<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744665</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107AUS37</org_study_id>
    <nct_id>NCT01744665</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.</brief_title>
  <acronym>ENESTgoal</acronym>
  <official_title>A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate molecular relapse free rates 6 months after stopping nilotinib therapy in
      patients who achieve MR4.5
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of patients without molecular relapse after stopping nilotinib</measure>
    <time_frame>6 months after stopping nilotinib therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of patients without confirmed loss of MR4 within 6 months following nilotinib TFR is calculated by dividing the number of patients with no documented confirmed loss of MR4, in the first 6 months after starting nilotinib TFR phase by the number of patients who entered nilotinib TFR phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients without molecular relapse after stopping nilotinib</measure>
    <time_frame>12, 18, and 36 months after stopping nilotinib</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients without confirmed loss of MR4 at 12, 18, and 36 months following nilotinib TFR is calculated by dividing the number of patients with no documented confirmed loss of MR4 at 12, 18, and 36 months after starting the nilotinib TFR phase by the number of patients who entered nilotinib TFR phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who regain MR4.5 after restarting nilotinib due to molecular relapse</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients who regain MR4.5 after restarting nilotinib will be calculated as the number of patients who achieve MR4.5 after having lost MR4 divided by the number of patients who lost MR4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression to AP/BC and death where the &quot;failure&quot; event is the earliest occurrence of the following event: progression to AP/BC or death from any cause.</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The estimation of progression-free survival (PFS) following nilotinib cessation will use the Kaplan-Meier (KM) method. PFS is measured from the date of cessation of nilotinib therapy to the date of the earliest of this event: progression to AP/BC or death from any cause. Patients not known to have progressed or died on or before the cut-off date for the KM analysis will have their PFS interval right-censored at the earlier of the date of their last assessment of molecular response status and the cut off date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) defined as the time from the date of cessation of nilotinib therapy to the date of death from any cause.</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Kaplan-Meier (KM) estimation of OS. OS is measured from the date of start of nilotinib TFR phase to the date of death from any cause. If a patient is not known to have died, survival will be censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival is defined as time from the date of nilotinib treatment discontinuation to the first documented molecular relapse (confirmed loss of MR4.0).</measure>
    <time_frame>7 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Kaplan- Meier (KM) estimation method in each arm. Patients who drop out without relapse will be treated as censored observations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptom-burden scores by the MDASI-CML assessment</measure>
    <time_frame>From baseline to time to when MR4.5 is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>The M.D. Anderson Symptom Inventory for CML patients (MDASI-CML) is a patient reported outcomes tool which will be used to assess the nature and impact of symptom burden on life on patients. The MDASI-CML consists of 19 validated symptom items and 6 validated core interference items. Each item is assessed on an 11 point scale, 0=Not Present and 10=&quot;As Bad as You can Imagine&quot;. The symptom, interference subscale total scores and the overall total score in MDASI-CML with their change from baseline will be summarized descriptively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in healthy utility assessed by EQ-5D-3L</measure>
    <time_frame>From baseline to time to when MR4.5 is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>The EQ-5D-3L questionnaire comprises 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression and the EQ visual analog scale. Each item has 3 levels (no problems, some problems and extreme problems) and visual analog has a scale 0 to 100 (0=worst imaginable health state, 100=best imaginable health state). The percentages of patients at each level of the five items of the EQ-5D-3L will be summarized overall and by treatments arms as appropriate at baseline and all post-baseline time points. Mean and standard deviation of the visual analog scale be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient quality of life assessed by SF-8</measure>
    <time_frame>From baseline to time to when MR4.5 is confirmed and from end of Consolidation Phase to 6 and 12 months into the TFR Phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>The SF-8 questionnaire consisting of 8 items (general health, physical functioning, rolephysical, bodily pain, vitality, social functioning, role-emotional and mental health) will be used to assess the impact of nilotinib treatment discontinuation on the quality of life. Each item has a 5 or 6 point response range. Physical and mental component summary measures (calculated using a norm-based scoring method given in the instrument guidelines) and each item score will be summarized at baseline and all post-baseline time points using mean and standard deviation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>CML</condition>
  <arm_group>
    <arm_group_label>AMN107 1 year of consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 patients will be enrolled to the study. Patients who achieve MR4.5 on study will then be randomized to receive a total of either 1 or 2 years of additional nilotinib therapy. If MR4.5 is sustained during the consolidation phase, patients will be eligible to stop taking niltoinib during the treatment-free remission (TFR) phase. No head to head comparison of the 2 arms will be performed. Each arm will be compared to historical data.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMN107 2 years of consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 patients will be enrolled to the study. Patients who achieve MR4.5 on study will then be randomized to receive a total of either 1 or 2 years (Consolidation Phase) of additional nilotinib therapy. If MR4.5 is sustained during the Consolidation phase, patients will be eligible to stop taking niltoinib during the treatment-free remission (TFR) phase. No head to head comparison of the 2 arms will be performed. Each arm will be compared to historical data.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMN107</intervention_name>
    <description>Nilotinib will be provided by the sponsor as the study drug. Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.</description>
    <arm_group_label>AMN107 1 year of consolidation</arm_group_label>
    <arm_group_label>AMN107 2 years of consolidation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of CML

          -  Treated with at least 1 year of imatinib

          -  Bcr-Abl level by PCR  must be less than or equal to 0.1% and greater than 0.0032% by
             PCR reported on the International scale. This will be confirmed during screening

          -  Written informed consent obtained prior to any screening procedures performed

        Exclusion Criteria:

          -  T315I mutation

          -  Prior imatinib failure or had accelerated phase or blast crisis CML

          -  Impaired cardiac function (defined futher in the protocol)

          -  Pregnant or lactating women

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center University of Alabama (8)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>205-934-0337</phone>
    </contact>
    <investigator>
      <last_name>Uma Borate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center Banner MD Anderson (2)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center Banner MD Anderson (2)</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-256-3620</phone>
    </contact>
    <investigator>
      <last_name>Rajesh Belani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare/TGen Clinical Research Service SC</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-323-1378</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Schriber</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group Corona Cancer Center</name>
      <address>
        <city>*see Various Departments*</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>951-898-2828</phone>
    </contact>
    <investigator>
      <last_name>Misagh Karimi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bay Area Cancer Research Dept.ofBayAreaCancerResearch</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 925 932 9700ext102</phone>
    </contact>
    <investigator>
      <last_name>Robert Robles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center Dept of Oncology</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 626 256 4673 60134</phone>
    </contact>
    <investigator>
      <last_name>David S Snyder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Compassionate Cancer Care Medical Group CCCMG</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-698-0300</phone>
    </contact>
    <investigator>
      <last_name>Haresh Jhangiani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego UC San Diego Cancer Ctr</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0987</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>858-534-7128</phone>
    </contact>
    <investigator>
      <last_name>Catriona Jamieson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epic-Care</name>
      <address>
        <city>Pleasant HIll</city>
        <state>California</state>
        <zip>94523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 925 676 3200 x 101</phone>
    </contact>
    <investigator>
      <last_name>Kasra Karamlou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Institute for Medical Research Oncology/Hematology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816-5199</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>916-453-3300</phone>
    </contact>
    <investigator>
      <last_name>Michael Carroll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group - Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>94503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>707-525-3930</phone>
    </contact>
    <investigator>
      <last_name>Marek Bozdech</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation Instit. of Hope and Innovation</name>
      <address>
        <city>Whitter</city>
        <state>California</state>
        <zip>90606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Berz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers USOR</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David J. Andorsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists DeptofFloridaCancerSpecialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>239-274-9930</phone>
      <email>CANN.askSarah@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Scott D. Lunin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center - Orlando Cancer Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>727-849-6690</phone>
    </contact>
    <investigator>
      <last_name>Julio Hajdenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute H. Lee Moffitt Cancer Ctr (67)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>813-745-1387</phone>
    </contact>
    <investigator>
      <last_name>Javier Pinilla-Ibarz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists. SC</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>770-496-9427</phone>
    </contact>
    <investigator>
      <last_name>Mansoor Saleh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stroger Cook County Hospital Division of Hematology &amp; Onc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>312-864-7257</phone>
    </contact>
    <investigator>
      <last_name>Rosalind Catchatourian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center Dept. of Univ. of Chicago Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>773-702-2119</phone>
    </contact>
    <investigator>
      <last_name>Richard A. Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Robert H. Lune Comprehensive</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Institute St. Francis Health</name>
      <address>
        <city>Beach Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-865-5500</phone>
    </contact>
    <investigator>
      <last_name>Luke P. Akard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics Holden Comprehensive Cancer Ct</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>319-356-2353</phone>
    </contact>
    <investigator>
      <last_name>Thomas Carter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center Clinical Research Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tara Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Witchita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>316-262-4467</phone>
    </contact>
    <investigator>
      <last_name>Shaker R. Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Clinic Hematology Oncology Clinic</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Castine III</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Schumpert Health System</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 318 681 6007</phone>
    </contact>
    <investigator>
      <last_name>Scott Scott Boniol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-368-3412</phone>
    </contact>
    <investigator>
      <last_name>Carole Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute D F C I</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Medical Center UMASS (6)</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>508-856-2509</phone>
    </contact>
    <investigator>
      <last_name>Jan Cerny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan State University / Breslin Cancer Center Breslin Cancer Center (3)</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>517-975-9547</phone>
    </contact>
    <investigator>
      <last_name>Anas Al-Janadi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Oncology Associates</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>601-974-5547</phone>
    </contact>
    <investigator>
      <last_name>Grace Shumaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic Billings Clinic (8)</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-554-8381</phone>
    </contact>
    <investigator>
      <last_name>Brock P Whittenberger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology &amp; Oncology Consultants, PC Hematology &amp; Oncology</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122-1799</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>VA Southern Nevada Healthcare System VA Southern Nevada Healthcare</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>702-807-6701</phone>
    </contact>
    <investigator>
      <last_name>Banshi Kashyap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Orange VA Medical Center Dept.ofHematology/Oncology(2)</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018-1095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>973-676-1000</phone>
    </contact>
    <investigator>
      <last_name>Shanti Srinivas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefan L. Faderl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Northern New Jersey PA Dept of Hem-Onc of Northern NJ</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>973-538-5149</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Scola</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Montefiore Medicial Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>718-920-4826</phone>
    </contact>
    <investigator>
      <last_name>Olga Derman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-Cornell University SC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-962-2700</phone>
    </contact>
    <investigator>
      <last_name>Eric J. Feldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center Herbert Irving Pavilion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-317-5199</phone>
    </contact>
    <investigator>
      <last_name>Mark Heaney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering (63)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-639-7762</phone>
    </contact>
    <investigator>
      <last_name>Ellin Berman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>585-275-2121</phone>
    </contact>
    <investigator>
      <last_name>Jane L. Liesveld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY- Stony Brook Medical Oncology Hematology/Oncology</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-746-2119</phone>
    </contact>
    <investigator>
      <last_name>Michael A. Schuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westchester Medical Center NY Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>914-493-8374</phone>
    </contact>
    <investigator>
      <last_name>Karen Seiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center Duke University Med Ctr</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-684-8964</phone>
    </contact>
    <investigator>
      <last_name>Joseph O Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Oncology Specialists, PC</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-889-5371</phone>
    </contact>
    <investigator>
      <last_name>Richard Orlowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center Hematology and Oncology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>336-716-4394</phone>
    </contact>
    <investigator>
      <last_name>Bayard L. Powell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State Comprehensive Cancer Center/James Cancer Hospital OSU Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>614-293-3321</phone>
    </contact>
    <investigator>
      <last_name>Rebecca Klisovic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohsu Ohsu (4)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-4603</phone>
    </contact>
    <investigator>
      <last_name>Michael J. Heinrich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists Compass Oncology -BKM</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>360-449-6522</phone>
    </contact>
    <investigator>
      <last_name>Kathryn S. Kolibaba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Carolina-Hollings Cancer Center Medical University of SC</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>843-792-9251</phone>
    </contact>
    <investigator>
      <last_name>Alice Mims</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Oncology Associates</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>864-255-1800</phone>
    </contact>
    <investigator>
      <last_name>Howland Crosswell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Dept. of Centennial Medical</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7252</phone>
      <email>CANN.askSarah@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Michael Savona</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univeristy Ingram Cancer Center (10)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-343-5374</phone>
    </contact>
    <investigator>
      <last_name>Sanjay Mohan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hendrick Cancer Center Hendricks Cancer Center</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>325-670-7342</phone>
    </contact>
    <investigator>
      <last_name>Jose A Vega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. Texas Oncology - Midland</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>432-687-1949</phone>
    </contact>
    <investigator>
      <last_name>David L. Watkins</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch SC</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>409-747-2211</phone>
    </contact>
    <investigator>
      <last_name>Mary Ninan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Cornell University</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-790-3333</phone>
    </contact>
    <investigator>
      <last_name>Swaminathan Iyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, Houston Medical School UT Physicians Oncology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>832-325-6520</phone>
    </contact>
    <investigator>
      <last_name>Adan Rios</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants Oncology Consultants, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-827-9525</phone>
    </contact>
    <investigator>
      <last_name>Julio Peguero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (14)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>713-206-6357</phone>
    </contact>
    <investigator>
      <last_name>Jorge E. Cortes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Oncology Hematology</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>South Texas Cancer Center- McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>956-687-5150</phone>
    </contact>
    <investigator>
      <last_name>Billie J. Marek</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Cancer Center- McAllen</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>956-687-5150</phone>
    </contact>
    <investigator>
      <last_name>Frederick Min</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center Brooke Army Medical</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alex Brown</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waco Cancer and Research Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>254-399-0741</phone>
    </contact>
    <investigator>
      <last_name>Robert J. Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Utah Cancer Associates Northern Utah Assoc (3)</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-387-7150</phone>
    </contact>
    <investigator>
      <last_name>Vincent Hansen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute Huntsman Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-581-6363</phone>
    </contact>
    <investigator>
      <last_name>Michael W. Deininger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Hematology/Oncology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael G. Douvas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, MCV Campus VA Commonwealth Univ.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prithvaraj Bose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology SC</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 509 783 4637 2</phone>
    </contact>
    <investigator>
      <last_name>Thomas Rado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University/ Mary Babb Randolph Cancer Center Mary Babb Randolph Cancer Ctr</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>304-598-4500</phone>
    </contact>
    <investigator>
      <last_name>Abraham D. Kanate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Med College of WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>414-805-4600</phone>
    </contact>
    <investigator>
      <last_name>Ehab Atallah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>December 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML, chronic myeloid leukemia, stop, niotinib, discontinue, imatinib, switch, MR4.5, undetectable, bcr-abl</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
